✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Parmax Pharma Ltd.

PARMAX

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹12 Cr.
P/E
0.00

Parmax Pharma Ltd.

  • Parmax Pharma
  • Cian Healthcare
  • Unjha Formulations

FAQs on Parmax Pharma Ltd. Shareprice

Parmax Pharma has given lower returns compared to its competitors.
Parmax Pharma has grown at ~-2.65% over the last 3yrs while peers have grown at a median rate of 21.9%

Parmax Pharma is not expensive.
Latest PE of Parmax Pharma is 0.0, while 3 year average PE is 26.57.
Also latest EV/EBITDA of Parmax Pharma is 0.0 while 3yr average is 63.32.

View FAQ's On Business

Growth Table

  • Parmax Pharma Ltd.
  • Cian Healthcare
  • Unjha Formulations

Balance Sheet

  • Parmax Pharma Ltd.
  • Cian Healthcare
  • Unjha Formulations

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Parmax Pharma Ltd.
  • Cian Healthcare
  • Unjha Formulations

Cash Flow

  • Parmax Pharma Ltd.
  • Cian Healthcare
  • Unjha Formulations

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Parmax Pharma Ltd.
  • Cian Healthcare
  • Unjha Formulations

Quarterly Results

  • Parmax Pharma Ltd.
  • Cian Healthcare
  • Unjha Formulations

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Parmax Pharma Ltd. Financials

Parmax Pharma balance sheet is weak and might have solvency issues

Yes, The net debt of Parmax Pharma is increasing.
Latest net debt of Parmax Pharma is ₹7.61 Crs as of Mar-25.
This is greater than Mar-24 when it was ₹5.81 Crs.

The profit is oscillating.
The profit of Parmax Pharma is -₹2.87 Crs for TTM, -₹5.78 Crs for Mar 2024 and -₹0.1 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Parmax Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech